

# Simultaneous RP-HPLC Estimation of Cefpodoxime Proxetil and Clavulanic Acid in Tablets

S. MALATHI\*, R. N. DUBEY AND R. VENKATNARAYANAN

Department of Pharmaceutical Analysis, RVS College of Pharmaceutical Sciences, Sulur, Coimbatore-641 402, India

Malathi *et al.*: Simultaneous Estimation of Cefpodoxime Proxetil and Clavulanic Acid

A new, simple, precise, rapid and accurate RP-HPLC method has been developed for the simultaneous estimation of cefpodoxime proxetil and clavulanic acid from pharmaceutical dosage forms. The method was carried out on a Zorbax Eclipse XDB 5  $\mu$  C 18 (150 $\times$ 4.6 mm) column with a mobile phase consisting of acetonitrile:50 mM potassium dihydrogen phosphate buffer (pH 3.0, 70:30 v/v) at a flow rate of 1.0 ml/min. Detection was carried out at 228 nm. Aspirin was used as an internal standard. The retention time of clavulanic acid, cefpodoxime proxetil and aspirin was 4.43, 6.44 and 5.6 min, respectively. The developed method was validated in terms of accuracy, precision, linearity, limit of detection, limit of quantification and solution stability. The proposed method can be used for the estimation of these drugs in combined dosage forms.

Key words: Cefpodoxime proxetil, clavulanic acid, RP-HPLC, isocratic

---

\*Address for correspondence

E-mail: mlth\_ml@yahoo.co.in


Cefpodoxime proxetil, chemically [(RS)-1 (isopropoxy carbonyloxy)ethyl(+)-(6R,7R)-7[2-(2-amino-4-thiazolyl)-2(Z)methoxyiminoacetamido]-3-methoxymethyl-8-oxo-5-thia-1-azabicyclo [4.2.0.]oct-2-ene-2-carboxylate], is a third generation cephalosporin antibiotic having activity against gram positive and gram negative micro organisms. Clavulanic acid is chemically [2-R-(2 $\alpha$ -3z,5 $\alpha$ )]-3-(2-hydroxyethylidene)-7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. It is used as a beta lactamase inhibitor, enhances the activity of penicillin and cephalosporin antibacterials against many resistant strains of bacteria. Many methods have been described in the literature for the determination of cefpodoxime proxetil and clavulanic acid individually and in combination with other drugs<sup>[1-6]</sup>. However, there is no HPLC method reported for the simultaneous estimation of these drugs in combined dosage forms. Fixed dose combination containing cefpodoxime proxetil (100 mg) and clavulanic acid (28.5 mg) is available in the tablet form in the market. The aim of this work was to develop an RP-HPLC method for the simultaneous determination of cefpodoxime proxetil and clavulanic acid in pharmaceutical dosage forms. The present RP-HPLC method was validated following the ICH guidelines<sup>[7,8]</sup>.

Acetonitrile HPLC grade, potassium dihydrogen orthophosphate and orthophosphoric acid AR grade were procured from Qualigens fine chemicals, Mumbai. Water HPLC grade was procured from S. D. Fine Chemicals. Reference standard of cefpodoxime proxetil and clavulanic acid were procured from Aurobindo Pharmaceuticals Ltd., Hyderabad, India and Cadila Pharmaceuticals Ltd., Ahmedabad, India.

Chromatographic separation was performed on a Shimadzu liquid chromatographic system equipped with a LC-10 VP solvent delivery system (Pump), SPD-10 vp UV/Vis detector, Rheodyne injector with 20  $\mu$ l loop volume. Spinchrom software was applied for data collecting and processing. A Zorbax Eclipse XDB C<sub>18</sub> column (150 $\times$ 4.6mm, 5  $\mu$ ) was used for the separation. The mobile phase was a mixture of acetonitrile and 50 mM potassium dihydrogenphosphate buffer (pH 3.0 adjusted with 10% orthophosphoric acid) (70:30 v/v). It was filtered through a 0.2  $\mu$  membrane filter and degassed. A flow rate of 1.0 ml/min and a detection wavelength of 228 nm were used. Standard stock solutions of (1 mg/ml) of cefpodoxime proxetil, clavulanic acid and aspirin were prepared separately using a

mixture of water and acetonitrile in the ratio 1:1 v/v. From the stock solution, mixed standard solution was prepared to contain 70  $\mu$ g/ml of cefpodoxime proxetil, 20  $\mu$ g/ml of clavulanic acid and 100  $\mu$ g/ml of aspirin as internal standard. Twenty tablets, each containing 100 mg of cefpodoxime proxetil and 28.5 mg of clavulanic acid (CV-CEF 128, Bestochem Pharmaceuticals, Pondicherry, India) were weighed and finely powdered; a quantity of powder equivalent to 35 mg of cefpodoxime proxetil and 10 mg of clavulanic acid was weighed and transferred in to a 100 ml volumetric flask and the drugs were extracted with the mixture of acetonitrile and water (1:1 v/v) and volume was made up to 100 ml with the same solvent. The solution was filtered using Whatman filter paper and the filtrate is referred to as formulation solution. Two milliliter of this solution was pipetted in to a 10 ml volumetric flask containing 1 ml of aspirin (1000  $\mu$ g/ml) as internal standard and this solution was used for the estimation.

With the optimized chromatographic conditions, a steady baseline was recorded. Twenty micro litres of the standard and formulation solutions were injected and the chromatogram was recorded (fig.1). The retention time of clavulanic acid, cefpodoxime proxetil and aspirin was found to be 4.43, 6.4 and 5.61min, respectively. The response factor (peak area ratio of



**Fig. 1: Typical chromatogram of sample solution**  
Liquid chromatogram showing well resolved peaks of clavulanic acid (4.4 min), aspirin (internal standard, 5.6 min) and cefpodoxime proxetil (6.4 min) using mobile phase of acetonitrile:50 mM potassium dihydrogen phosphate buffer (pH 3.0) 70:30 v/v.

standard peak area and internal standard peak area) of the standard solution and sample solution were calculated. The concentration of drugs were calculated (Table 1) using following formula, Concentration of drugs= (response factor of the sample/response factor of the standard)×concentration of standard. The peak area ratio of standard and sample solutions was calculated. The assay procedure was repeated six times and mean peak area ratio and mean weight of standard drugs were calculated. The percentage of individual drugs found in formulation, mean, standard deviation in formulation were calculated and presented in Table 1. The results of analysis showed that the calculated amount of drug was in good agreement with the label claim of the formulation. The linearity of the method was determined at five concentration levels ranging from 70 to 350 µg/ml for cefpodoxime proxetil and 20 to 100 µg/ml for clavulanic acid. The calibration curve was constructed by plotting response factor against concentration of drugs. The slope and intercept value for calibration curve was  $y=0.0057x+0.0566$  ( $R^2=0.998$ ) for cefpodoxime proxetil and  $y=0.0023x+0.0628$  ( $R^2=0.999$ ) for clavulanic acid. The results show that an excellent correlation exists between response factor and concentration range indicated above.

The method was validated as per ICH guidelines. The accuracy of the method was determined by recovery experiments. The recovery studies were carried out six times and the percentage recovery and standard deviation of the percentage recovery were calculated and are presented in Table 1. From the data obtained,

added recoveries of standard drugs were found to be accurate.

The precision of the method was demonstrated by inter day and intra day variation studies. In the intraday studies, six repeated injections of standard and sample solutions were made and the response factor of drug peaks and percentage RSD were calculated. In the inter day variation studies, six repeated injections of standard and sample solutions were made for three consecutive days and response factor of drug peaks and percentage RSD were calculated. From the data obtained, the developed HPLC method was found to be precise. The limit of detection (LOD) and the limit of quantification (LOQ) of the developed method were determined by injecting progressively low concentrations of the standard solutions using the developed RP-HPLC method. The LOD is the smallest concentration of the analyte that gives a measurable response (signal to noise ratio of 3). The LOD for cefpodoxime proxetil and clavulanic acid was found to be 5 µg/ml and 3 µg/ml, respectively. The LOQ is the smallest concentration of the analyte, which gives response that can be accurately quantified (signal to noise ratio of 10). The LOQ for cefpodoxime proxetil and clavulanic acid was found to be 12 µg/ml and 10 µg/ml, respectively (Table 2).

Ruggedness of the method was determined by carrying out the experiment on different time intervals and on different days. Robustness of the method was determined by making slight changes in the

**TABLE 1: RESULTS OF ANALYSIS OF FORMULATION AND RECOVERY STUDIES**

| Drug                 | Amount mg/tab |        | %Label claim* | % Recovery* |
|----------------------|---------------|--------|---------------|-------------|
|                      | Labelled      | Found* |               |             |
| Cefpodoxime proxetil | 100           | 98.95  | 98.95±0.39    | 101.12      |
| Clavulanic acid      | 28.5          | 29.18  | 102.42±0.52   | 100.23      |

\*RSD of six observations

**TABLE 2: VALIDATION AND SYSTEM SUITABILITY STUDIES**

| Parameters               | Cefpodoxime Proxetil | Clavulanic acid      |
|--------------------------|----------------------|----------------------|
| Linearity range          | 70-350 µg/ml         | 20-100 µg/ml         |
| Regression equation      |                      | $y = 0.0023x+0.0628$ |
| $Y= mx+c^*$              | $y = 0.0057x+0.0566$ |                      |
| Correlation coefficient  | 0.9982               | 0.9993               |
| Theoretical plates/meter | 3146                 | 3825                 |
| Resolution factor        | 2.0089               | 3.3636               |
| Asymmetric factor        | 1.0                  | 1.30                 |
| LOD (µg/ml)              | 5                    | 3                    |
| LOQ (µg/ml)              | 12                   | 10                   |

\* $y=mx+c$ , m: slope c: y axis intercept

**TABLE 3: ROBUSTNESS PARAMETERS**

| Parameter             | Variation | Effect on chromatogram |                 |                 |                 |
|-----------------------|-----------|------------------------|-----------------|-----------------|-----------------|
|                       |           | Cefpodoxime proxetil   |                 | Clavulanic acid |                 |
|                       |           | Normal RT              | After variation | Normal RT       | After variation |
| Ratio of mobile phase | 72:28     | 6.4                    | 6.3             | 4.4             | 4.3             |
|                       | 68:32     | 6.4                    | 6.4             | 4.4             | 4.5             |
| Peak shape            |           | sharp                  | sharp           | sharp           | sharp           |
| Flow rate             | 1.2 ml    | 6.4                    | 5.6             | 4.4             | 3.7             |
|                       | 0.8 ml    | 6.4                    | 7.0             | 4.4             | 5.5             |
| Peak shape            |           | sharp                  | sharp           | sharp           | sharp           |
| pH                    | 3.2       | 6.4                    | 6.2             | 4.4             | 4.2             |
|                       | 2.8       | 6.4                    | 6.4             | 4.4             | 4.5             |
| Peak Shape            |           | sharp                  | sharp           | sharp           | sharp           |

RT = Retention time

chromatographic conditions (Table 3). No marked changes in the chromatograms demonstrated that the HPLC method developed is rugged and robust. In order to demonstrate the stability of both standard and sample solutions during analysis, both solutions were analyzed over a period of 5 h at room temperature. The results show that for both solutions, the retention time and peak area of cefpodoxime proxetil and clavulanic acid remained almost unchanged (% RSD is less than 2) with no significant degradation within the period, indicated that both solutions were stable for at least 5 h, which was sufficient to complete the whole analytical process.

The system suitability studies were carried out to determine theoretical plate/meter, resolution factor, asymmetric factor and tailing factor. The results are given in Table 2. The values obtained demonstrated the suitability of the system for the analysis of this drug combination, system suitability parameters may fall within  $\pm 3\%$  standard deviation range during routine performance of the method. Overall, the proposed RP-HPLC method for the simultaneous estimation of cefpodoxime proxetil and clavulanic acid in combined dosage forms is accurate, precise, linear, robust, simple and rapid.

## ACKNOWLEDGEMENTS

The authors are grateful to the Principal and the

management, R. V. S. College of Pharmaceutical Sciences, Sulur, Coimbatore, for providing the required facilities to carry out this research work and Tamilnadu Pharmaceutical Science Welfare Trust, Chennai for awarding scholarship for this work.

## REFERENCES

1. Shah PB, Pundarikakshudu K. RP-HPLC for the determination of cefpodoxime proxetil. *Indian Drugs* 2006;43:126-8.
2. Kakumanu VK, Arora VK, Bansal AK. Development and validation of isomer specific RP HPLC method for quantification of cefpodoxime proxetil. *J Chromatogr B* 2006;835:16-20.
3. Shah PB, Pundarikakshudu K. Spectroscopic method for the determination of cefpodoxime proxetil. *Indian Drugs* 2005;42:94-7.
4. Darji BH, Shah NJ, Patel AT, Patel NM. Development and validation of HPTLC method for the estimation of cefpodoxime proxetil. *Indian J Pharm Sci* 2007;69:331-3.
5. Campus F, Deslandes A, Harcouet L, Farinotti R. High performance liquid chromatographic method for the determination of cefpodoxime level in plasma and sinus mucosa. *J Chromatogr B Biomed Appl* 1994;656:383-8.
6. Yoon KH, Lee SY, Jong W, Park S. Simultaneous determination of amoxicillin and clavulanic acid in human plasma by HPLC-ESI Mass spectrometry. *J Chromatogr B* 2004;813:121-7.
7. ICH, Q2A Text on Validation of analytical procedure, International Conference on Harmonization, Geneva 1995.
8. ICH-Q2B, Validation of analytical procedure: Methodology, International Conference on Harmonization, Geneva 1996 March.

Accepted 13 February 2009

Revised 22 August 2008

Received 14 February 2008

Indian J. Pharm. Sci., 2009, 71 (1): 102-105